{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:03:13Z","timestamp":1790794993664,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer Oy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s41669-024-00524-4","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T10:43:44Z","timestamp":1725619424000},"page":"57-68","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Healthcare Resource Utilization and Associated Costs During the First 5\u00a0Years After Diagnosis and at the End of Life: A Nationwide Cohort Study of Patients with Multiple Myeloma in Finland"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0908-5288","authenticated-orcid":false,"given":"Mikko","family":"Kosunen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1056-3838","authenticated-orcid":false,"given":"Jarno","family":"Ruotsalainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7269-0421","authenticated-orcid":false,"given":"Alvar","family":"Kallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7342-5797","authenticated-orcid":false,"given":"Roope","family":"Mets\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4207-8415","authenticated-orcid":false,"given":"Paavo","family":"Raittinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0494-3900","authenticated-orcid":false,"given":"Leena","family":"Lehmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2953-4757","authenticated-orcid":false,"given":"Maarit J.","family":"Korhonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7794-7495","authenticated-orcid":false,"given":"Timo","family":"Purmonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"issue":"9","key":"524_CR1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","volume":"10","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9):94. https:\/\/doi.org\/10.1038\/s41408-020-00359-2.","journal-title":"Blood Cancer J"},{"key":"524_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05571-1","author":"J Ruotsalainen","year":"2023","unstructured":"Ruotsalainen J, Lehmus L, Putkonen M, et al. Recent trends in incidence, survival and treatment of multiple myeloma in Finland\u2014a nationwide cohort study. Ann Hematol. 2023. https:\/\/doi.org\/10.1007\/s00277-023-05571-1.","journal-title":"Ann Hematol"},{"key":"524_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200208001-00014","author":"ML Brown","year":"2002","unstructured":"Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002. https:\/\/doi.org\/10.1097\/00005650-200208001-00014.","journal-title":"Med Care"},{"issue":"1","key":"524_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1186\/s12885-016-2835-7","volume":"16","author":"C de Oliveira","year":"2016","unstructured":"de Oliveira C, Pataky R, Bremner KE, et al. Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer. 2016;16(1):809. https:\/\/doi.org\/10.1186\/s12885-016-2835-7.","journal-title":"BMC Cancer"},{"issue":"11","key":"524_CR5","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/bjc.2016.77","volume":"114","author":"M Laudicella","year":"2016","unstructured":"Laudicella M, Walsh B, Burns E, Smith PC. Cost of care for cancer patients in England: evidence from population-based patient-level data. Br J Cancer. 2016;114(11):1286\u201392. https:\/\/doi.org\/10.1038\/bjc.2016.77.","journal-title":"Br J Cancer"},{"issue":"26","key":"524_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026523","volume":"100","author":"C Bugge","year":"2021","unstructured":"Bugge C, Brustugun OT, S\u00e6ther EM, Kristiansen IS. Phase- and gender-specific, lifetime, and future costs of cancer: a retrospective population-based registry study. Medicine (Baltimore). 2021;100(26): e26523. https:\/\/doi.org\/10.1097\/MD.0000000000026523.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"524_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10198-022-01463-9","volume":"24","author":"A Bessou","year":"2023","unstructured":"Bessou A, Colin X, De Nascimento J, et al. Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 (SNDS) database: a retrospective cohort study. Eur J Health Econ. 2023;24(3):321\u201333. https:\/\/doi.org\/10.1007\/s10198-022-01463-9.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"524_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/EJH.13615","volume":"107","author":"LH Hannig","year":"2021","unstructured":"Hannig LH, Nielsen LK, Ibsen R, Arnheim-Dahlstr\u00f6m L, Kjellberg J, Abildgaard N. The impact of changed treatment patterns in multiple myeloma on health-care utilisation and costs, myeloma complications, and survival: a population-based comparison between two time periods in Denmark. Eur J Haematol. 2021;107(1):63\u201373. https:\/\/doi.org\/10.1111\/EJH.13615.","journal-title":"Eur J Haematol"},{"issue":"5","key":"524_CR9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s40273-020-00993-5","volume":"39","author":"M Neves","year":"2021","unstructured":"Neves M, Trigo F, Rui B, et al. Multiple myeloma in Portugal: burden of disease and cost of illness. Pharmacoeconomics. 2021;39(5):579\u201387. https:\/\/doi.org\/10.1007\/s40273-020-00993-5.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"524_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1365-2354.2009.01153.x","volume":"20","author":"D Koleva","year":"2011","unstructured":"Koleva D, Cortelazzo S, Toldo C, Garattini L. Healthcare costs of multiple myeloma: an Italian study. Eur J Cancer Care (Engl). 2011;20(3):330\u20136. https:\/\/doi.org\/10.1111\/j.1365-2354.2009.01153.x.","journal-title":"Eur J Cancer Care (Engl)."},{"issue":"30","key":"524_CR11","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.2217\/fon-2023-0120","volume":"19","author":"J Vikkula","year":"2023","unstructured":"Vikkula J, Uusi-Rauva K, Ranki T, et al. Real-world evidence of multiple myeloma treated from 2013 to 2019 in the hospital district of Helsinki and Uusimaa, Finland. Future Oncol. 2023;19(30):2029\u201343. https:\/\/doi.org\/10.2217\/fon-2023-0120.","journal-title":"Future Oncol"},{"issue":"6","key":"524_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000913","volume":"7","author":"C Bennink","year":"2023","unstructured":"Bennink C, Westgeest H, Schoonen D, et al. High hospital-related costs at the end-of-life in patients with multiple myeloma: a single-center study. Hemasphere. 2023;7(6): e913. https:\/\/doi.org\/10.1097\/HS9.0000000000000913.","journal-title":"Hemasphere"},{"key":"524_CR13","unstructured":"Ministry of Social Affairs and Health. Wellbeing services counties. https:\/\/stm.fi\/en\/wellbeing-services-counties. Accessed February 29, 2024."},{"key":"524_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/CLEP.S282475","volume":"13","author":"JF Ludvigsson","year":"2021","unstructured":"Ludvigsson JF, Appelros P, Askling J, et al. Adaptation of the Charlson comorbidity index for register-based research in Sweden. Clin Epidemiol. 2021;13:21\u201341. https:\/\/doi.org\/10.2147\/CLEP.S282475.","journal-title":"Clin Epidemiol"},{"key":"524_CR15","unstructured":"M\u00e4klin S, Kokko P. Terveyden- ja sosiaalihuollon yksikk\u00f6kustannukset Suomessa vuonna 2017. Terveyden ja hyvinvoinnin laitos (Institute of Health and Welfare). 2021. https:\/\/www.julkari.fi\/handle\/10024\/142882. Accessed 19 Jan 2024."},{"key":"524_CR16","unstructured":"Statistics Finland. Price index of public expenditure, PxWeb. https:\/\/pxdata.stat.fi:443\/PxWebPxWeb\/pxweb\/en\/StatFin\/StatFin__jmhi\/statfin_jmhi_pxt_11m2.px\/. Accessed July 31, 2024."},{"issue":"3","key":"524_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/ejh.14119","volume":"112","author":"MR Seefat","year":"2024","unstructured":"Seefat MR, Cucchi DGJ, Groen K, et al. Treatment sequences and drug costs from diagnosis to death in multiple myeloma. Eur J Haematol. 2024;112(3):360\u20136. https:\/\/doi.org\/10.1111\/ejh.14119.","journal-title":"Eur J Haematol"},{"issue":"7","key":"524_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.16357","volume":"4","author":"K Bhattacharya","year":"2021","unstructured":"Bhattacharya K, Bentley JP, Ramachandran S, et al. Phase-specific and lifetime costs of multiple myeloma among older adults in the US. JAMA Netw Open. 2021;4(7): e2116357. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.16357.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"524_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.11648\/j.ijcems.20210701.14","volume":"7","author":"S Torvinen","year":"2021","unstructured":"Torvinen S, Vihervaara V, Miettinen T, et al. Multiple myeloma treatments, outcomes, and costs of health care resource utilisation during 2009\u20132016, based on multiple data sources from a hospital district in Finland. Int J Clin Exp Med Sci. 2021;7(1):21\u201330. https:\/\/doi.org\/10.11648\/j.ijcems.20210701.14.","journal-title":"Int J Clin Exp Med Sci"},{"issue":"5","key":"524_CR20","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s41669-023-00430-1","volume":"7","author":"AHS Vestergaard","year":"2023","unstructured":"Vestergaard AHS, Ehlers LH, Neergaard MA, Christiansen CF, Valentin JB, Johnsen SP. Healthcare costs at the end of life for patients with non-cancer diseases and cancer in Denmark. Pharmacoecon Open. 2023;7(5):751\u201364. https:\/\/doi.org\/10.1007\/s41669-023-00430-1.","journal-title":"Pharmacoecon Open"},{"issue":"7","key":"524_CR21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/0284186X.2018.1438656","volume":"57","author":"P Torkki","year":"2018","unstructured":"Torkki P, Leskel\u00e4 RL, Linna M, et al. Cancer costs and outcomes for common cancer sites in the Finnish population between 2009\u20132014. Acta Oncol. 2018;57(7):983\u20138. https:\/\/doi.org\/10.1080\/0284186X.2018.1438656.","journal-title":"Acta Oncol"},{"key":"524_CR22","unstructured":"Yhden sy\u00f6p\u00e4l\u00e4\u00e4kkeen hintakilpailu s\u00e4\u00e4sti kymmeni\u00e4 miljoonia\u2014l\u00e4\u00e4kkeiden patenttisuojien p\u00e4\u00e4ttymisess\u00e4 on l\u00e4hivuosina suuri s\u00e4\u00e4st\u00f6potentiaali. KELA | FPA. https:\/\/www.kela.fi\/mediatiedotteet\/5264836\/. Accessed February 29, 2024."},{"issue":"1","key":"524_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12962-022-00391-y","volume":"20","author":"K Hernandez-Villafuerte","year":"2022","unstructured":"Hernandez-Villafuerte K, Zamora B, Feng Y, Parkin D, Devlin N, Towse A. Estimating health system opportunity costs: the role of non-linearities and inefficiency. Cost Eff Resour Alloc. 2022;20(1):56. https:\/\/doi.org\/10.1186\/s12962-022-00391-y.","journal-title":"Cost Eff Resour Alloc"},{"issue":"4","key":"524_CR24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1177\/0272989X20916450","volume":"40","author":"MO Soares","year":"2020","unstructured":"Soares MO, Sculpher MJ, Claxton K. Health opportunity costs: assessing the implications of uncertainty using elicitation methods with experts. Med Decis Making. 2020;40(4):448\u201359. https:\/\/doi.org\/10.1177\/0272989X20916450.","journal-title":"Med Decis Making"},{"issue":"6","key":"524_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/1403494812456637","volume":"40","author":"R Sund","year":"2012","unstructured":"Sund R. Quality of the Finnish hospital discharge register: a systematic review. Scand J Public Health. 2012;40(6):505\u201315. https:\/\/doi.org\/10.1177\/1403494812456637.","journal-title":"Scand J Public Health"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00524-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-024-00524-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00524-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T13:03:51Z","timestamp":1736427831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-024-00524-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["524"],"URL":"https:\/\/doi.org\/10.1007\/s41669-024-00524-4","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"assertion":[{"value":"21 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Pfizer Oy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MK and LL are employed by Pfizer Oy and own Pfizer stocks. RM is a former employee of Pfizer Oy and owned Pfizer stocks at the time of this work. JR, AK, PR, MJK and TP are employees of Oriola Finland Oy, which received funding from Pfizer Oy in connection with the development of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interests"}},{"value":"This article does not contain any studies with human participants performed by any of the authors. This register-based study was approved by each register holder.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication (from Patients\/Participants)"}},{"value":"Research data are not shared. The data are available with the permission of The Finnish Social and Health Data Permit Authority. Thus, the data are not publicly available.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The code used in the data management and analysis can be made available upon reasonable request to the authors.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MK, JR, RM, LL, MJK and TP contributed to the study design and objectives, interpretation of results and revising the manuscript. AK and PR were responsible for data analysis. MK and JR were responsible for manuscript development. All authors have reviewed and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}